 |
Vinod Labhasetwar, Ph.D.StaffDepartment of Biomedical Engineering (ND20) |
Area of general research interest:
Our focus is on translational NanoMedicine, which involves biomaterial synthesis, formulation design and development, and evaluation of different biocompatible nanoparticle-based platform technologies for targeted drug/gene delivery and imaging agents. Our current primary research interests are in cancer treatment and detection, delivery of anti-oxidant enzymes in stroke and development of a non-stent approach to inhibition of restenosis.
Current programs:
- Polymer synthesis, nanoparticle formulation, functionalization, characterization
- Molecular mechanisms of nanoparticle-cell interactions, uptake and intracellular trafficking, and drug efficacy
- Developing nanoparticles as non-viral gene expression vector
- Multifunctional magnetic nanoparticles for drug delivery, optical imaging, and magnetic resonance imaging
- Cancer treatment, drug resistance, drug combination, drug targeting, 3-D tumor model, metastatic tumor models
- Stroke, vascular diseases, CNS delivery of anti-HIV drugs
- Biocompatibility of nanosystems, interactions with model membrane, oxidative stress, clearance
- Biophysical interactions with model cell plasma membrane, engineering nanoparticles to modulate drug resistance
- Functionalized nanoparticles for drug targeting, CNS delivery of anti-HIV drugs
Personnel:
- Isaac Adjei (Graduate Student)
- Radhika Bhave (Graduate Student)
- Sanja Dimitrijevic, D.V.M. (Research Technologist)
- Adekunle Elegbede (Medical Student)
- Susan Foy (Graduate Student)
- Shan Lu (Graduate Student)
- Mircea Pavkov, M.D., Ph.D. (Research Fellow)
- Chiranjeevi Peetla, Ph.D. (Research Fellow)
- Blanka Sharma, Ph.D. (Research Fellow)
- Sivakumar Vijayaraghavalu, Ph.D.
Collaborators:
- Ernest C. Borden, M.D., Taussig Cancer Institute, Cleveland Clinic
- Chris Flask, Ph.D., Case Western Reserve University, Cleveland, OH
- Anuja Ghorpade, Ph.D., University of North Texas Health Science Center, Dallas, TX
- Warren Heston, Ph.D., Cancer Biology, Cleveland Clinic
- Cynthia J. Meininger, Ph.D., Texas A&M Health Science Center, Temple, TX
- Derek Raghavan, M.D., Ph.D., F.A.C.P., F.R.A.C.P., Taussig Cancer Institute, Cleveland Clinic
- Yogen Saunthararajah, M.D., Taussig Cancer Center, Cleveland Clinic
- Maciej Zborowski, Ph.D., Biomedical Engineering, Cleveland Clinic